/

SRPT

Sarepta Therapeutics, Inc.Open

16.94−0.50 −2.87%USD

NasdaqGS · as of Oct 13, 10:18 ET · 15m delay

Open

17.12

Prev close

17.44

Day range

16.8717.23

52-week range

14.6824.68

Volume

304.06K0.10×

Mkt cap

1.79B

P/E ttm

—

Fwd P/E

7.06

EPS ttm

-1.57

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−31.36%

Price Chart

Yahoo Finance · delayed

SRPTOct 13, 2026O 17.12H 17.23L 16.87C 16.94−0.50 (−2.87%)Vol 304.06K

SMA 5019.13
SMA 20018.98

1Y change −23.38% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

SRPT Sarepta Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.14%
1 month: −17.16%
3 months: −5.68%
6 months: −23.52%
Year to date: −21.28%
1 year: −22.86%

Valuation & ownership

Market cap: 1.79B
Enterprise value: 2.12B
P/E (ttm): —
Forward P/E: 7.06
PEG ratio: -0.09
Price / book: 1.17
Price / sales (ttm): 0.91
EV / EBITDA: -120.69
EPS (ttm): -1.57
EPS (forward): 2.40
Beta (5y monthly): 0.38
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 105.63M
Float: 100.54M
Short % of float: 25.85%
Short ratio (days): 7.77
Held by insiders: 4.89%
Held by institutions: 104.10%
Avg volume (3m): 3.00M
50-day average: 19.11
200-day average: 19.00
52-week change: −22.86%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 37.0
vs 50-day SMA: −11.46%
vs 200-day SMA: −10.74%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.62%
Realised vol (20d, ann.): 50.9%
From 52-week high: −31.36%
From 52-week low: +15.40%

ANR

Analyst Consensus

22 analysts

Consensus

Hold

2.75 on a 1 (strong buy) – 5 (sell) scale

Mean target

21.64

+27.72% implied

Low 5.00Median 20.00High 38.00

Recommendation trend

Now7 / 12 / 5
1m ago

DES

About Sarepta Therapeutics, Inc.

Yahoo Finance profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 835
Headquarters: Cambridge, MA, United States
Website: sarepta.com
Officers: Mr. Ian Michael Estepan President & COO

SEAS

Seasonality · SRPT

2007–2026 · monthly returns

Strongest month May +10.91%Weakest month Oct −6.61%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.5	-17.6	29.8	-4.0	-14.4	0.6	-17.3	41.5	-13.4	-7.0			−21.3%
2025	-6.5	-6.1	-40.2	-2.2	-39.7	-54.5	-4.0	10.8	5.9	24.6	-11.1	0.8	−82.3%
2024	23.4	7.5	1.2	-2.2	2.5	21.7	-10.0	-4.5	-8.0	0.9	5.8	-8.8	+26.1%
2023	-3.6	-2.3	12.9	-10.9	0.7	-7.3	-5.4	11.6	0.2	-44.5	20.8	18.6	−25.6%
2022	-20.5	7.0	2.0	-7.4	0.7	2.9	24.0	17.7	1.1	3.1	7.7	5.5	+43.9%
2021	-47.6	-2.6	-14.4	-5.0	6.8	2.8	-12.8	15.3	18.4	-14.4	2.1	11.4	−47.2%
2020	-10.1	-1.3	-14.5	20.5	29.2	5.3	-4.3	-4.6	-4.1	-3.2	3.6	21.0	+32.1%
2019	28.0	3.2	-17.4	-1.9	-2.6	33.5	-2.0	-39.4	-16.5	10.3	35.4	14.7	+18.2%
2018	17.8	-4.2	18.0	3.1	22.9	40.8	-12.1	18.8	17.0	-17.2	-3.2	-15.7	+96.1%
2017	13.2	0.2	-4.9	22.5	-17.7	13.0	14.4	4.4	12.6	8.7	12.9	-0.1	+102.8%
2016	-69.2	15.4	42.4	-27.3	47.5	-8.9	32.6	3.1	135.6	-36.1	-12.7	-19.9	−28.9%
2015	-17.1	15.8	-4.5	-8.1	110.0	18.8	4.9	11.8	-10.1	-25.1	52.8	5.0	+166.6%
2014	19.7	19.1	-17.2	54.5	-9.3	-11.5	-28.4	7.5	-8.0	-23.4	4.8	-14.6	−29.0%
2013	4.8	8.3	26.1	-21.4	21.7	7.6	-2.8	-7.7	38.4	-17.6	-52.1	9.3	−21.0%
2012	20.0	15.6	48.1	-46.1	-21.7	-3.1	139.9	74.4	-1.8	37.3	37.5	-12.0	+473.3%
2011	2.4	-7.8	-7.0	-3.8	-10.1	-11.2	2.8	-15.6	-9.7	-12.5	-25.5	2.7	−64.6%
2010	0.0	-1.4	-18.1	11.9	8.3	12.6	21.1	7.2	-12.4	15.8	-13.2	15.2	+45.2%
2009	31.8	-31.0	10.0	22.7	50.6	29.5	45.6	-25.7	0.6	-14.5	-3.4	2.8	+121.2%
2008	-12.1	9.7	35.3	-18.5	-6.7	-20.0	9.8	-8.9	8.0	-28.9	-24.4	1.5	−53.2%
2007	-4.7	-12.2	0.8	-0.4	14.2	-8.2	-7.1	0.4	-2.3	11.0	-17.7	-39.5	−55.7%

INSD

Insider Activity · SRPT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 27, 2026	Severino Michael EChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	756.1K	—
Jun 3, 2026	Behrens M KathleenDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Connelly Deirdre PDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Barry Richard JDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Wigzell Hans Lennart RudolfDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Nicaise ClaudeDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Boor Kathryn JeanDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Mayo Stephen L.Director	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Jun 3, 2026	Chambers Michael AndrewDirector	Stock Award(Grant) at price 0.00 per share.	16.9K	—
Mar 11, 2026	Mayo Stephen L.Director	Sale at price 17.02 per share.	7.2K	$123.21K
Feb 26, 2026	Rodino-Klapac LouiseOfficer	—	8.1K	—
Feb 26, 2026	Estepan Ian MichaelChief Operating Officer	—	8.1K	—
Feb 25, 2026	Estepan Ian MichaelChief Operating Officer	Conversion of Exercise of derivative security at price 13.71 per share.	7.5K	$102.14K
Jan 28, 2026	Nicaise ClaudeDirector	Conversion of Exercise of derivative security at price 13.71 per share.	10.5K	$143.96K
Jan 26, 2026	Behrens M KathleenDirector	Conversion of Exercise of derivative security at price 13.71 per share.	10.5K	$143.96K
Dec 15, 2025	Estepan Ian MichaelChief Operating Officer	Sale at price 22.31 per share.	13.2K	$294.20K
Dec 4, 2025	Ingram Douglas SChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	539.1K	—
Sep 2, 2025	Rodino-Klapac LouiseOfficer	Stock Award(Grant) at price 0.00 per share.	143.9K	—
Sep 2, 2025	Estepan Ian MichaelChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	143.9K	—
Sep 2, 2025	Rothfuss CristinGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	118.9K	—

CONG

Congress Trades · SRPT

House and Senate reports since 2025

Members

0 last bought

Buys

~$0

Sells

~$8.0K

Net

−$8.0K

est. bought − sold

Latest

Apr 14, 25

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31		1	−$8.0K	Sold Apr 14, 25

Bought and sold by quarter (est.)

Members of Congress's SRPT trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Apr 14, 25	Gilbert Cisneros CA31	Self	Sell	$1,001 - $15,000	May 6, 25 (22d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

13F

Investors Holding SRPT

latest 13F filings of 29 followed managers

Investors holding SRPT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$20.2M	0.03%	1.12M	−33%	Q2 2026
Oaktree Capital · Howard Marks	$6.3M	0.09%	6.71M	New	Q2 2026
Bridgewater Associates · Ray Dalio	$2.7M	0.01%	152.07K	+13%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

SRPT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

SRPT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Sarepta Therapeutics, Inc.

Seasonality · SRPT

Insider Activity · SRPT

Congress Trades · SRPT

Members who traded it

Bought and sold by quarter (est.)

Investors Holding SRPT

Investors Holding SRPT

Congress Trades · SRPT

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · SRPT

Seasonality · SRPT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Sarepta Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News